pharmacotherapy for osteoarthritis (OA) alleviates pain and inflammation but does not protect the articular cartilage from further damage or affect disease progression. Biological markers such as YKL-40 may provide a snapshot of current events in joint tissues, allowing rapid assessment of treatments. This review discusses recent data regarding YKL-40, with an emphasis on the relationship between YKL-40 and OA. The presence of YKL-40 in cartilage and synovium in OA patients correlates with histopathological changes and may reflect local disease activity. In addition, the levels of YKL-40 in serum and synovial fluid also seem to correlate with disease severity. The functional role of YKL-40 is not yet clear, but its production as part of the inflammatory response in articular chondrocytes may modulate the cellular response to proinflammatory cytokines, acting to limit connective tissue degradation. Further elucidation of its roles and relationships may enable YKL-40 to act as a useful biomarker in the development of therapies for OA.
Introduction
Osteoarthritis (OA) is a highly prevalent disease characterized by progressive degeneration of the articular cartilage and damage to subchondral bone. OA is part of the ageing process, but its aetiology remains far from clear. The major features of OA are cartilage degradation and loss, but the disease process also affects the synovial membrane, subchondral bone, ligaments and peri-articular muscles. The factors responsible for the onset of OA and the stimulation of chondrocyte proliferation in cell clusters are unknown, as is the phenotype of hyperactive OA chondrocytes. While numerous studies have provided detailed insights into the morphological and biochemical aspects of OA, the molecular mechanisms underlying the progressive loss of articular cartilage during OA development remain largely unknown.
There are few biomarkers available for the diagnosis of early stage OA and, so far, none has entered routine clinical use for monitoring disease activity in OA patients. The ideal biological marker should generally possess the following characteristics: it should be a perfectly characterized compound that can be assayed using a single, reliable technique; it should be specific to the formation or resorption of a given joint tissue; it should accurately K Huang, LD Wu YKL-40: a potential biomarker for osteoarthritis discriminate patients from controls; it should accurately predict or vary in parallel with changes in structural lesions; and it should be useful for the rapid assessment of the effect of an OA treatment. There is great interest in identifying and characterizing the possible role of some cytokines, such as YKL-40 or hyaluronic acid, which may be useful for diagnosing OA and predicting its progression.
In recent years a growing number of studies have been published concerning chitinases and chitinase-like molecules, including YKL-40. 1 -5 It has been suggested that YKL-40 is a surrogate marker of synovial inflammation and joint destruction in OA. 6 -8 Amino acid sequence analysis reveals that YKL-40 belongs to glycohydrolase family 18, but complete characterization of its in vivo biological functions remains to be established. In the present review, the potentially important roles of YKL-40 in OA are examined on the basis of recent studies.
Characterization of YKL-40 and its expression in different cells and tissues
The protein, YKL-40, which is also known as chitinase-3-like protein 1 or human cartilage glycoprotein 39, belongs to family 18 of the mammalian glycosyl hydrolases, which are homologous to the chitinases of lower organisms, including bacterial chitinases as well as vertebrate and invertebrate chitinases. 9 -12 The name of the protein is derived from its molecular weight (40 kDa) and the single-letter codes for its three Nterminal amino acids (tyrosine, lysine and leucine). The three-dimensional crystal structure of YKL-40 displays folding typical of family 18 glycosyl hydrolases. The structure is divided into two globular domains: a large core domain consisting of a (β/α) eight-domain structure with a triose phosphate isomerase (TIM) barrel fold, and a small α/β domain comprising five anti-parallel βstrands and one α-helix that is inserted in the loop between strand β7 and helix α7 of the TIM barrel. This provides the active site of YKL-40 with a groove-like character.
YKL-40 can be secreted by several different cell types in the joint tissue, including macrophages, articular chondrocytes and synoviocytes. 9,13 -16 Rehli et al. 17 showed that YKL-40 mRNA expression is absent in normal human monocytes in vitro, but is strongly induced during the late stages of human macrophage differentiation. Expression of YKL-40 mRNA and protein in vivo has been reported in a subpopulation of macrophages participating in inflammatory and extracellular matrix (ECM) remodelling processes in different tissues. 18 -20 Microarray cDNA analyses have shown that YKL-40 gene expression is upregulated in dedifferentiated human fetal chondrocytes relative to differentiated chondrocytes. 21 Redifferentiation of dedifferentiated chondrocytes in vitro increases YKL-40 expression, as measured by cDNA analysis; this result is also observed with in vitro chondrogenesis, indicating that YKL-40 is a differentiation marker in chondrocytes. 22 Synoviocytes are another main cell type in the joint tissue that can secrete YKL-40 during various inflammatory reactions. 6 Dasuri et al. 23 studied synoviocyte proteins using two-dimensional polyacrylamide gel electrophoresis and matrix-assisted laser desorption ionization mass spectrometry and found that YKL-40 is a major cellular protein in these cells. YKL-40 is also expressed by osteoblasts and the primary osteocytes present in osteophytes. 24, 25 However, YKL-40 is not specific to joint tissue; it has also been recovered from mammary secretions, 26 an osteosarcoma cell line, 25 K Huang, LD Wu YKL-40: a potential biomarker for osteoarthritis neutrophil granules 27 and herniated human lumbar discs. 28 The mRNA of YKL-40 is highly expressed in the liver 29, 30 and, to a lesser extent, in the brain, kidney and placenta. 4, 9, 31 
Regulation of YKL-40 by cytokines
The molecular processes governing the induction of YKL-40 are currently unknown. How the expression of YKL-40 is regulated at the transcriptional level has been explored in some studies, 32 -34 but remains somewhat controversial. Transforming growth factor-β (TGF-β) reduces the level of YKL-40 mRNA in human chondrocytes 9, 35 as well as the amount of YKL-40 secreted from guinea-pig chondrocytes, 36 whereas expression does not seem to be influenced by interleukin (IL)-1β or tumour necrosis factor-α (TNF-α) in human synovial cells 13 and guinea-pig articular chondrocytes. 36 However, Johansen et al. 37 reported that IL-1β and TGF-β decreased the secretion of YKL-40 by chondrocyte monolayer cultures and that this was associated with a reduction in YKL-40 mRNA levels. IL-1β, but not TGF-β, reduced YKL-40 production in cartilage explant cultures. No inhibitory effects of TGF-β were found during treatment but, when stimulation with TGF-β was stopped, YKL-40 production increased significantly compared with that in non-stimulated explants. 37 Interestingly, this was not the case in another study in neonatal rat chondrocytes: 38 the inflammatory cytokines TNF-α and IL-1 potently induced steady-state levels of YKL-40 mRNA and protein secretion. Treatment of chondrocytes with TNF-α for as little as 1 h was sufficient for sustained induction up to 72 h afterwards. YKL-40 synthesis was induced in rat articular chondrocytes by the inflammatory cytokines, TNF-α and IL-1, and this process was uniquely dependent on the activity of the transcription factor, nuclear factor-κB (NF-κB). 38 Insulin-like growth factor-1 (IGF-1) was reported to have no effect on the expression of YKL-40 mRNA in human chondrocytes, 9 but increased the level of YKL-40 in conditioned media from guineapig articular chondrocytes. 36 The controversy concerning the effect of different cytokines, including IL-1β, TNF-α, TGF-β and IGF-1, on YKL-40 expression may be due to differences in species, donor age, doses and tissue conditions between the various studies reported in the literature.
Factors that stimulate YKL-40 production in OA
YKL-40 is secreted from human articular cartilage explants or isolated human chondrocytes in culture, although its expression in vivo is restricted to older and osteoarthritic cartilage. 39 Normal cartilage explant cultures produce low levels of YKL-40 during the first few days of culture, after which YKL-40 secretion begins to increase. Freshly isolated chondrocytes from normal cartilage do not secrete YKL-40 during the first days of monolayer culture, but cells in first-passage monolayer cultures produce higher levels of YKL-40 than primary chondrocyte cultures, suggesting that chondrocytes rapidly synthesize large amounts of YKL-40 in response to changes in the biochemical or biomechanical environment. Chondrocytes cultured as a monolayer or in suspension with methacrylate secrete large amounts of YKL-40, and this production is prevented if the chondrocytes are cultured in alginate, in which case the cells are already surrounded by ECM. Furthermore, the secretion of YKL-40 from cartilage explants in culture diminishes with time, although renewed K Huang, LD Wu YKL-40: a potential biomarker for osteoarthritis cutting of the explants appears to restore secretion levels, 37 suggesting that YKL-40 production is an injury response of the tissue. Volck et al. 18, 39 further reported that YKL-40-positive chondrocytes are found in the superficial and middle layers of OA cartilage from hip or knee joints. Various ECM components in these tissues are degraded, providing further support for the concept that matrix injury triggers production of YKL-40.
The above studies demonstrate that three main factors stimulate YKL-40 production: (i) changes in the biochemical or biomechanical environment; (ii) removal of chondrocytes from their native ECM environment; and (iii) injury to the cartilage matrix. These three factors may be the mechanisms of high YKL-40 production in OA, since OA chondrocytes alter their gene expression patterns in response to changes in their surrounding matrix, the mechanical properties of the cartilage, and various growth factors, cytokines and inflammatory mediators. An inability adequately to repair the ECM will prolong the exposure of the chondrocytes to an abnormal and stressful environment, resulting in continued YKL-40 expression.
YKL-40 expression in cartilage and synovial membranes in OA
In situ hybridization analyses have demonstrated that YKL-40 mRNA is undetectable in chondrocytes from normal articular cartilage, but it is expressed at moderate to high levels in chondrocytes that are located in the superficial zone of articular cartilage from patients with mild OA and, more frequently, in weight-bearing areas of the hip joint. In advanced OA, chondrocytes located in the superficial, middle and deep layers express YKL-40 and this expression increases with increasing extent of tissue damage. 24, 40 Johansen et al. 37 showed that the basal secretion of YKL-40 from OA cartilage explant cultures was significantly higher than from normal cartilage explant cultures during the first 24 h of culture; even after 5 days in culture, the former showed a higher level of YKL-40 secretion. Immunohistochemical analyses detected YKL-40 protein expression in chondrocytes located in both the superficial and middle layers of cartilage biopsies from OA patients. 39 -41 This observation of increased YKL-40 production by chondrocytes in diseased tissue is consistent with the findings of Hakala et al., 9 who demonstrated high expression of YKL-40 mRNA in arthritic cartilage but not in normal cartilage.
In addition to osteoarthritic cartilage, synovial membranes are another major tissue that secretes YKL-40 in OA. Immunohistochemical analysis of synovial membranes from OA patients demonstrated that YKL-40-positive cells were found in lining and stromal cells (macrophages) and that the number of YKL-40-positive cells correlated with the severity of the synovitis. 18, 40 Taken together, these studies indicate that the presence of YKL-40 in the cartilage and synovium of knee joints in OA patients correlates with histopathological changes in these tissues. YKL-40 may, therefore, be involved in the pathophysiology of the osteoarthritic processes and may reflect local disease activity involving articular cartilage degradation and synovial inflammation and so may be a useful biomarker of OA.
YKL-40 levels in serum and synovial fluid in OA
Levels of YKL-40 in the serum and synovial fluid can be measured by radioimmunoassay 42 or enzyme-linked immunosorbent K Huang, LD Wu YKL-40: a potential biomarker for osteoarthritis assay. 43 One study found that patients with late-stage OA of the knee had significantly higher serum YKL-40 levels than agematched healthy subjects, whereas serum YKL-40 levels in patients with early-stage OA of the knee or recent torn cruciate ligaments or menisci were not elevated. A similar pattern has also been reported for YKL-40 in the synovial fluid. 44 A correlation exists between the levels of YKL-40 in serum and in synovial fluid, although the levels in synovial fluid are approximately 10-fold higher than in serum. 42, 44 Another study reported similar results, in which the positive correlation between YKL-40 in serum and in the synovial fluid of knee joints was consistent with joint synovitis in the knee and the predominance of synovial tissue in the knee joint, suggesting that correlations between YKL-40 concentrations in the synovial fluid and serum reflect changes in the global amount of synovial fluid and synovial tissue. 18 Assessment of serum and synovial fluid YKL-40 may provide new and direct information with regard to local disease activity as well as pathophysiological processes in the osteoarthritic joint.
The possible role of YKL-40 in OA
The high level of YKL-40 expression in OA patients raises the question about the function of YKL-40 in OA. In this regard, De Ceuninck et al. 45 reported that YKL-40 increases proteoglycan synthesis in guineapig and rabbit chondrocytes, suggesting that YKL-40 may assist self-repair of the ECM during the progression of OA. In addition, YKL-40 dampens the response of chondrocytes and synovial cells to the inflammatory cytokines TNF-α and IL-1, thereby reducing the production of chemokines and matrix metalloproteases, 46 which play critical roles in ECM destruction in OA. These observations suggest that YKL-40 has a protective role in inflammatory environments, limiting the degradation of the ECM and, thus, controlling tissue damage. 47, 48 As YKL-40 production is part of the inflammatory response in articular chondrocytes, the regulation of YKL-40 expression can serve as a feedback mechanism to modulate the cellular response to pro-inflammatory cytokines and limit connective tissue degradation in OA.
Future perspectives
Current pharmacotherapies function only to alleviate the mild to moderate pain and inflammation that are associated with OA. They do not protect the articular cartilage from further damage, nor have they been shown to be useful for affecting disease progression. Intensive research focused on identifying the role of YKL-40 in OA may result in important implications for drug design, since biological markers such as YKL-40, may provide a snapshot of current events in the joint tissues, allowing rapid assessment of treatment effects. However, many problems surrounding the use of YKL-40 as a biomarker remain to be solved. What are the mediators that are involved in upregulating YKL-40 activity in human OA? How are the activities of these proteases modulated by mechanisms such as transcriptional regulation or posttranslational activation or processing? What are the potential consequences of their stimulation or inhibition? What are the functions of YKL-40 in other organs and tissues? Addressing these and other questions will be critical for the development of therapeutic agents to treat OA.
